All > Metastatic Lung Cancer > Lung Cancer

BI 907828 treatment arm for Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
UNIV UZ Gent, Gent, BelgiumLung Cancer+4 MoreBI 907828 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. It examines whether a medicine called BI 907828 can help when other treatments have been unsuccessful. Participants take the medicine regularly and are monitored for changes in their health.

Eligible Conditions
  • Lung Cancer
  • Bladder Cancer
  • Solid Tumors
  • Biliary Tract Cancer
  • Pancreatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
BI 765049
1
Cohort A: Ezabenlimab + BI 765063
1
BI 1569912

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: Up to 50 months

Up to 30 months
Change from baseline in EORTC QLQ-BIL21 tiredness domain score
Change from baseline in EORTC QLQ-C30 fatigue domain score
Change from baseline in EORTC QLQ-C30 role functioning domain score
Change from baseline in European Organisation for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ)-C30 physical functioning domain score
Disease control (DC)
Duration of objective response (DOR)
Objective response (OR)
Therapeutic procedure
Occurrence of treatment-emergent adverse events (AEs) during the on-treatment period
Progression-free survival (PFS)
Up to 50 months
Overall survival (OS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
BI 765049
1
Cohort A: Ezabenlimab + BI 765063
1
BI 1569912

Trial Design

1 Treatment Group

BI 907828 treatment arm
1 of 1

Experimental Treatment

130 Total Participants · 1 Treatment Group

Primary Treatment: BI 907828 treatment arm · No Placebo Group · Phase 2

BI 907828 treatment arm
Drug
Experimental Group · 1 Intervention: BI 907828 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 50 months

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,398 Previous Clinical Trials
9,800,878 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have been diagnosed with a type of cancer that is part of the clinical trial.
You have advanced or metastatic cancer in your bile ducts, gallbladder or ampulla. You have already received all known treatments for your cancer or you cannot tolerate or benefit from standard treatments.
You have advanced or spreading lung adenocarcinoma that cannot be surgically removed. You have already tried all the usual treatments that are known to help your condition.
References

Frequently Asked Questions

How many individuals are currently enrolled in this experiment?

"Affirmative. According to information provided on clinicaltrials.gov, the medical trial is actively seeking qualified candidates and was initially posted in late November 2022 before its most recent update occurring on March 6th 2023. 130 participants must be sourced from a total of 18 sites for this study." - Anonymous Online Contributor

Unverified Answer

Is this research endeavor available for enrollment currently?

"Clinicaltrials.gov reveals that this clinical trial is still recruiting participants; it was initially posted on November 25th 2022 and underwent its latest revision on March 6th 2023." - Anonymous Online Contributor

Unverified Answer

Has the BI 907828 treatment arm obtained clearance from the FDA?

"Due to the lack of efficacy data, BI 907828's safety is estimated at a rating of 2. Although it has been through Phase 2 trials and there are some results indicating its security." - Anonymous Online Contributor

Unverified Answer

How many venues are providing data for this research?

"Presently, this research is occurring in 18 centres situated across Washington, Hat Yai and Bangkok. It is prudent for potential participants to select the closest location possible so as to reduce their travel costs should they choose to enroll." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top